We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Extension Granted to DxS and BTG for ARMS Technology Licence Parameters
News

Extension Granted to DxS and BTG for ARMS Technology Licence Parameters

Extension Granted to DxS and BTG for ARMS Technology Licence Parameters
News

Extension Granted to DxS and BTG for ARMS Technology Licence Parameters

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Extension Granted to DxS and BTG for ARMS Technology Licence Parameters"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BTG and DxS have announced an extension and improvement to the licences they are able to provide for use of the Amplification Refractory Mutation System (ARMSTM).

ARMS is a method for the detection of gene mutations and single nucleotide polymorphisms.

Under an extension to their licence agreement with AstraZenecaBTG and DxS are now able to grant licences under the technology rights to ARMS and related technologies from a combination of the licensable rights under both AstraZeneca and City of Hope patents (patent numbers US 5,595,890, US 5,137,806, US 5,639,611 and corresponding patents worldwide).

In March 2004, an agreement was signed with AstraZeneca giving DxS and BTG certain rights to the intellectual property with the aim of further commercialising the technology within the diagnostic and research markets.

The extension will allow DxS and BTG to maximise the commercial value for the ARMS™ technology.

This is being achieved via companies that offer products and services that relate to the detection of genetic variation, companies that are currently using ARMS™ technology as part of their in-house research activities, as well as encouraging applications for this technology.

Amplification Refractory Mutation System technology, as licensed from DxS and BTG, is a well-established and reliable method for the detection of genetic variations and single nucleotide polymorphisms.

Scientists believe SNP maps will help them identify the multiple genes associated with such complex diseases as cancer, diabetes, and vascular disease. 

In addition, SNPs can help determine the likelihood that someone will develop a particular disease. 

Furthermore, SNPs are useful in predetermining an individual's response to drug treatment, and can be used as markers to differentiate individuals with varying response to treatment.

Advertisement